Place · Level 3 · Condition
Dyslipidemia · understanding cholesterol
ApoB > LDL-C · 看心血管风险, 不单看数字 · 他汀是 A 级证据 · 饮食改 < 10-15%, 别期望饮食一项治根
Last updated
Story path
- 1Cholesterol · not a single numberCholesterol · not a single number
- 2Statins · A-grade evidence + real concernsStatins · A-grade evidence + real concerns
- 3Mechanism · how plaque growsMechanism · how plaque grows
- 4Diet + lifestyle · realistic effectsDiet + lifestyle · realistic effects
- 5My lipid panel is off — what now?My lipid panel is off — what now?
Chapter 1
Cholesterol · not a single number
Cholesterol · not a single number
Dyslipidemia is the #1 modifiable risk factor for atherosclerotic cardiovascular disease (atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease.). Key knowledge: 'high cholesterol' is not about the TC (total cholesterol) number alone — it's about the atherogenic components.
Core indicators:
LDL-C: 'bad cholesterol', causally linked to ASCVDhigh-density lipoprotein cholesterol: The so-called 'good cholesterol' — it helps ferry excess cholesterol back to the liver.: 'good cholesterol', inversely associated (recent evidence challenges its causal protective role)TG (triglycerides): high TG reflects insulin resistance and independently increases risknon-HDL-C = TC - HDL-C: covers all atherogenic particlesapolipoprotein B: One sits on every artery-clogging particle, so counting it counts the harmful particles directly.: direct count of atherogenic particles, more accurate than LDL-C (especially with high TG / diabetes / obesity)lipoprotein(a): A largely gene-set lipoprotein particle that independently raises cardiovascular risk.: strongly genetically determined independent risk factor, measure at least onceRemnant cholesterol = TC − LDL-C − HDL-C: the cholesterol in triglyceride-rich lipoprotein remnants, a driver of residual risk independent of LDL (Mendelian randomization suggests causality; risk rises above roughly 1.0 mmol/L)
Risk stratification (composite, not just numbers):
Very high risk: established ASCVD event / DM + target organ damageHigh risk: 10-year ASCVD risk ≥ 20% / severe risk factor (LDL-C ≥ 4.9 / severe HTN / long-standing DM)Moderate risk: 10-year risk 7.5-19.9%Low risk: < 7.5%
Key risk calculators:
PCE (Pooled Cohort Equations) — US AHA/ACCSCORE2 — European ESC, regional versions existChina-PAR — China-calibrated, recommended for Chinese populations
low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls. targets (by risk tier, not 'lower is always better' blanket):
Low risk: < 3.0 mmol/L (116 mg/dL)Moderate risk: < 2.6 mmol/L (100 mg/dL)High risk: < 1.8 mmol/L (70 mg/dL) + LDL-C ↓ ≥ 50% from baselineVery high risk: < 1.4 mmol/L (55 mg/dL)
Core indicators:
LDL-C: 'bad cholesterol', causally linked to ASCVDhigh-density lipoprotein cholesterol: The so-called 'good cholesterol' — it helps ferry excess cholesterol back to the liver.: 'good cholesterol', inversely associated (recent evidence challenges its causal protective role)TG (triglycerides): high TG reflects insulin resistance and independently increases risknon-HDL-C = TC - HDL-C: covers all atherogenic particlesapolipoprotein B: One sits on every artery-clogging particle, so counting it counts the harmful particles directly.: direct count of atherogenic particles, more accurate than LDL-C (especially with high TG / diabetes / obesity)lipoprotein(a): A largely gene-set lipoprotein particle that independently raises cardiovascular risk.: strongly genetically determined independent risk factor, measure at least onceRemnant cholesterol = TC − LDL-C − HDL-C: the cholesterol in triglyceride-rich lipoprotein remnants, a driver of residual risk independent of LDL (Mendelian randomization suggests causality; risk rises above roughly 1.0 mmol/L)
Risk stratification (composite, not just numbers):
Very high risk: established ASCVD event / DM + target organ damageHigh risk: 10-year ASCVD risk ≥ 20% / severe risk factor (LDL-C ≥ 4.9 / severe HTN / long-standing DM)Moderate risk: 10-year risk 7.5-19.9%Low risk: < 7.5%
Key risk calculators:
PCE (Pooled Cohort Equations) — US AHA/ACCSCORE2 — European ESC, regional versions existChina-PAR — China-calibrated, recommended for Chinese populations
low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls. targets (by risk tier, not 'lower is always better' blanket):
Low risk: < 3.0 mmol/L (116 mg/dL)Moderate risk: < 2.6 mmol/L (100 mg/dL)High risk: < 1.8 mmol/L (70 mg/dL) + LDL-C ↓ ≥ 50% from baselineVery high risk: < 1.4 mmol/L (55 mg/dL)
指标定义 + 风险分层 + LDL 目标值
血脂异常是动脉粥样硬化性心血管病 (atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease. —— 就是心梗、卒中那一类) 最值得管、也最管得动的风险。所以看血脂高不高, 不能只数总胆固醇 (TC) 那一行, 要看里面真正致病的成分。报告上那几行数字, 各自说的是不同的事。low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls. (低密度脂蛋白胆固醇) 就是俗称的坏胆固醇, 和血管出事有直接因果; high-density lipoprotein cholesterol: The so-called 'good cholesterol' — it helps ferry excess cholesterol back to the liver. (好胆固醇) 方向相反, 数值高一般更好 (不过近年证据提示它更像风险的旁观者, 而不是主动的保护者)。甘油三酯 (TG) 偏高, 往往是身体对胰岛素不敏感的信号, 它自己也会推高风险。想把这些致病颗粒一起算, 有两个更全的指标: non-HDL-C (总胆固醇减掉 HDL-C) 和 apolipoprotein B: One sits on every artery-clogging particle, so counting it counts the harmful particles directly.——ApoB 是直接数颗粒的个数, 在甘油三酯高、糖尿病、肥胖的人身上比 LDL-C 更准 (下一层细讲)。还有两项容易被漏掉: lipoprotein(a): A largely gene-set lipoprotein particle that independently raises cardiovascular risk. 由基因决定, 一生至少测一次就行; 残余胆固醇 (甘油三酯富集颗粒里带着的那点胆固醇) 是独立于 LDL 之外的一份额外风险。
那到底该把 LDL 压到多低? 这不是越低越好一刀切, 而是看你落在哪一档风险。已经出过 ASCVD 事件 (心梗、卒中), 或糖尿病已经伤到靶器官的, 属于极高危; 十年 ASCVD 风险到 20% 以上 (或 LDL-C 本身就 ≥ 4.9 mmol/L 这类严重情况) 算高危; 7.5-19.9% 是中危; 7.5% 以下是低危。算这个十年风险有现成工具——美国用 PCE、欧洲用 SCORE2、中国人推荐用按本地人群校准的 China-PAR。风险越高, LDL 的目标线就越严:
低危: < 3.0 mmol/L (116 mg/dL)中危: < 2.6 mmol/L (100 mg/dL)高危: < 1.8 mmol/L (70 mg/dL), 并且比原来至少再降一半极高危: < 1.4 mmol/L (55 mg/dL)
ApoB + particle number · why some with 'normal' LDL-C still have events
There is a clinically useful concept the public rarely hears: what is atherogenic is the number of lipoprotein particles, not how much cholesterol each particle carries. Grasping this explains why some people with seemingly 'normal' low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls. still have cardiovascular events.Every cholesterol-carrying particle in blood (LDL, VLDL, lipoprotein(a): A largely gene-set lipoprotein particle that independently raises cardiovascular risk., etc.) wears one apolipoprotein B: One sits on every artery-clogging particle, so counting it counts the harmful particles directly. protein — one particle, one ApoB. So measuring ApoB directly counts how many particles can burrow into the artery wall. LDL-C measures the total cholesterol inside those particles — and if a person's particles are small and dense (common with high triglycerides, diabetes, obesity), the same LDL-C number can hide far more particles. That is why people with 'normal LDL-C but high ApoB' have their risk underestimated.
Atherosclerosis begins when these ApoB-bearing particles burrow under the endothelium, get oxidized, and recruit macrophages that engulf them into foam cells. The more particles, the more chances to burrow in. So particle number (ApoB) tracks the true causal chain more closely than cholesterol content (LDL-C).
In practice: for most people LDL-C and ApoB agree closely, and LDL-C is enough. But in those with high triglycerides, diabetes, obesity, or LDL-C 'at goal' yet still high-risk, adding one ApoB measurement gives a more accurate stratification.
Lp(a) is another long-overlooked particle: it is genetically set, barely moved by diet or exercise, and high Lp(a) is an independent risk factor for cardiovascular disease and aortic stenosis. Guidelines recommend measuring it at least once in a lifetime, so you know whether you carry an inborn high-risk constitution.
Chapter 2
Statins · A-grade evidence + real concerns
Statins · A-grade evidence + real concerns
In plain words first: statins are the most thoroughly studied lipid-lowering drug, and one that genuinely cuts heart attacks and strokes; the online 'statins are toxic, full of side effects' claims mostly don't survive scrutiny. Below we lay the evidence and the concerns out point by point — judge for yourself.
Statins are one of the best-evidenced classes in medicine.
CTT 2010 Lancet meta-analysis (n = 170,000, 26 RCTs):
Each 1 mmol/L LDL-C reduction → major CV events ↓ 22% + all-cause mortality ↓ 10%Effect consistent across all subgroups (men/women / young/old / DM/no DM)5-year absolute benefit: in high-risk patients, 5 events prevented per 100 treated
Indications (primary + secondary prevention):
Secondary prevention (established atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease.): almost everyone, high-intensity statinPrimary prevention (no ASCVD):LDL-C ≥ 4.9 mmol/L: direct statin, no risk-calculator neededDM age 40-75 + LDL-C 1.8-4.9: moderate-intensity statin10-year ASCVD risk ≥ 7.5%: shared decision, lean toward statin
Real-world concerns — the scientific response:
'Statins hurt the liver': serious hepatotoxicity < 0.01%. Routine LFT monitoring offers no benefit. Mild transaminase elevation doesn't require discontinuation.'Statin myalgia (SAMS)': real RCT rate < 5%, observational 10-20% (strong nocebo effect). Most resolve with switching or dose reduction.'Statins cause diabetes': real but minimal (5-year NNH ~ 200) vs CV benefit (NNT ~ 50). High-intensity statins slightly higher. Net benefit overwhelming.'Statins cause dementia': no evidence. Early FDA warning based on weak signal, large subsequent studies refuted it.'Statins are deadly': no evidence. CTT meta shows reduced all-cause mortality.
Statin intolerance:
True intolerance < 5%. Most SAMS is nocebo or comorbid (vitamin D deficiency / hypothyroid)Management: dose reduction / switch / alternate-day / add CoQ10 (limited evidence)True intolerance → ezetimibe + PCSK9 inhibitor (alirocumab/evolocumab) + Bempedoic acid
Newer drugs (high-risk patients with off-target low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls.):
PCSK9i (evolocumab, alirocumab): LDL-C ↓ 50-60%, CV events ↓ 15-20%, injectable, expensiveInclisiran (siRNA, every 6 months): more convenient, long-term data maturingBempedoic acid: doesn't enter muscle, suited to statin-intolerant patients; the CLEAR Outcomes RCT (Nissen 2023, 13,970 statin-intolerant patients) showed major cardiovascular events ↓ 13% (↓ 30% in the primary-prevention subgroup) — the first hard-endpoint evidence for this grouplipoprotein(a): A largely gene-set lipoprotein particle that independently raises cardiovascular risk.-specific (Pelacarsen): Phase III, 2025-2026 data expected
Red yeast rice truth:
Contains natural statin (monacolin K) — chemically = lovastatinNot a 'natural statin alternative' — same statin side effectsQuality varies: impurities + inconsistent content, not recommended as a substitute for prescription statinsSee atlas supplements/red-yeast-rice for detail
Statins are one of the best-evidenced classes in medicine.
CTT 2010 Lancet meta-analysis (n = 170,000, 26 RCTs):
Each 1 mmol/L LDL-C reduction → major CV events ↓ 22% + all-cause mortality ↓ 10%Effect consistent across all subgroups (men/women / young/old / DM/no DM)5-year absolute benefit: in high-risk patients, 5 events prevented per 100 treated
Indications (primary + secondary prevention):
Secondary prevention (established atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease.): almost everyone, high-intensity statinPrimary prevention (no ASCVD):LDL-C ≥ 4.9 mmol/L: direct statin, no risk-calculator neededDM age 40-75 + LDL-C 1.8-4.9: moderate-intensity statin10-year ASCVD risk ≥ 7.5%: shared decision, lean toward statin
Real-world concerns — the scientific response:
'Statins hurt the liver': serious hepatotoxicity < 0.01%. Routine LFT monitoring offers no benefit. Mild transaminase elevation doesn't require discontinuation.'Statin myalgia (SAMS)': real RCT rate < 5%, observational 10-20% (strong nocebo effect). Most resolve with switching or dose reduction.'Statins cause diabetes': real but minimal (5-year NNH ~ 200) vs CV benefit (NNT ~ 50). High-intensity statins slightly higher. Net benefit overwhelming.'Statins cause dementia': no evidence. Early FDA warning based on weak signal, large subsequent studies refuted it.'Statins are deadly': no evidence. CTT meta shows reduced all-cause mortality.
Statin intolerance:
True intolerance < 5%. Most SAMS is nocebo or comorbid (vitamin D deficiency / hypothyroid)Management: dose reduction / switch / alternate-day / add CoQ10 (limited evidence)True intolerance → ezetimibe + PCSK9 inhibitor (alirocumab/evolocumab) + Bempedoic acid
Newer drugs (high-risk patients with off-target low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls.):
PCSK9i (evolocumab, alirocumab): LDL-C ↓ 50-60%, CV events ↓ 15-20%, injectable, expensiveInclisiran (siRNA, every 6 months): more convenient, long-term data maturingBempedoic acid: doesn't enter muscle, suited to statin-intolerant patients; the CLEAR Outcomes RCT (Nissen 2023, 13,970 statin-intolerant patients) showed major cardiovascular events ↓ 13% (↓ 30% in the primary-prevention subgroup) — the first hard-endpoint evidence for this grouplipoprotein(a): A largely gene-set lipoprotein particle that independently raises cardiovascular risk.-specific (Pelacarsen): Phase III, 2025-2026 data expected
Red yeast rice truth:
Contains natural statin (monacolin K) — chemically = lovastatinNot a 'natural statin alternative' — same statin side effectsQuality varies: impurities + inconsistent content, not recommended as a substitute for prescription statinsSee atlas supplements/red-yeast-rice for detail
Mechanism · how statins lower LDL, and why it's more than a number
Statins work more elegantly than the public imagines. They do not 'flush cholesterol out of the blood' directly — they act on the liver cell's supply-and-demand.The liver is the main cholesterol-synthesis factory, and its key rate-limiting enzyme is HMG-CoA reductase. A statin's chemical structure mimics this enzyme's substrate, occupies it, and inhibits hepatic cholesterol synthesis. When the liver cell senses it is short on cholesterol, it up-regulates surface LDL receptors and pulls more LDL particles back out of the blood. The result: blood LDL particles are cleared by the liver, and low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls. and apolipoprotein B: One sits on every artery-clogging particle, so counting it counts the harmful particles directly. fall together. That is why, in the CTT meta-analysis, every 1 mmol/L LDL-C drop reliably lowers risk — what falls is the particle count that actually burrows into the artery wall.
Statins also have 'pleiotropic effects': plaque stabilization and reduced vascular inflammation (echoing the inflammation-atherosclerosis axis in atlas chronic-inflammation). So statin benefit is not solely the LDL-C number dropping; plaque stabilization itself lowers acute events.
Lipid-lowering intensity comes in three tiers:
High intensity (atorvastatin 40-80 mg / rosuvastatin 20-40 mg): LDL-C ↓ ≥ 50%Moderate: LDL-C ↓ 30-49%Low: LDL-C ↓ < 30%
Secondary prevention (established atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease.) usually uses high intensity; primary prevention picks intensity by risk tier. The point is not 'I took a statin' but 'I reached target' — if off-goal, the dose should rise or a combination drug (ezetimibe / PCSK9i) be added.
Chapter 3
Mechanism · how plaque grows
Mechanism · how plaque grows
Why does high LDL take decades to cause an event? Because atherosclerosis is a quiet, decades-long accumulation. Seeing this line clearly explains why clinicians prefer to lower LDL earlier and gently, rather than waiting for symptoms.
Step 1 · Particles burrow into the artery wall:
apolipoprotein B: One sits on every artery-clogging particle, so counting it counts the harmful particles directly.-bearing lipoproteins (mainly LDL) seep from the bloodstream under the endotheliumHigh blood pressure, smoking, and high glucose damage the endothelium, easing entryThe more particles (higher ApoB), the more chances to enter — this is the meaning of 'lowering particle number'
Step 2 · Oxidation + inflammation:
The burrowed-in LDL gets oxidized (oxidized LDL)Oxidized LDL recruits the immune system: monocytes enter the intima and become macrophagesMacrophages engulf oxidized LDL → become lipid-laden 'foam cells'This step is inflammation-driven, echoing atlas chronic-inflammation: atherosclerosis is essentially a chronic vascular inflammation (Libby 2011)
Step 3 · Plaque forms:
Foam cells accumulate → a lipid core formsSmooth-muscle cells migrate and secrete collagen → a fibrous cap forms over the lipid coreThis is an 'atherosclerotic plaque'
Step 4 · Plaque rupture → acute event:
Stable plaque (thick cap + small lipid core): may just narrow slowly over yearsUnstable plaque (thin cap + large lipid core + strong inflammation): prone to ruptureRupture → platelet aggregation → thrombus → acute occlusion → heart attack / strokeMany heart attacks occur on plaques that only narrow the vessel 30-50% — danger comes not from how narrow it is but from how unstable it is
Why this mechanism dictates the treatment philosophy:
Lowering LDL / ApoB = less raw material burrowing into the wall → plaque progression slows or even regressesThe extra value of statins is plaque stabilization (lowering inflammation), not just lowering a numberControlling blood pressure + quitting smoking + controlling glucose = protecting the endothelium, fewer particles enteringThis is why a single low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls. number is not enough — what matters is the overall 'will plaque grow, and is it stable'
Step 1 · Particles burrow into the artery wall:
apolipoprotein B: One sits on every artery-clogging particle, so counting it counts the harmful particles directly.-bearing lipoproteins (mainly LDL) seep from the bloodstream under the endotheliumHigh blood pressure, smoking, and high glucose damage the endothelium, easing entryThe more particles (higher ApoB), the more chances to enter — this is the meaning of 'lowering particle number'
Step 2 · Oxidation + inflammation:
The burrowed-in LDL gets oxidized (oxidized LDL)Oxidized LDL recruits the immune system: monocytes enter the intima and become macrophagesMacrophages engulf oxidized LDL → become lipid-laden 'foam cells'This step is inflammation-driven, echoing atlas chronic-inflammation: atherosclerosis is essentially a chronic vascular inflammation (Libby 2011)
Step 3 · Plaque forms:
Foam cells accumulate → a lipid core formsSmooth-muscle cells migrate and secrete collagen → a fibrous cap forms over the lipid coreThis is an 'atherosclerotic plaque'
Step 4 · Plaque rupture → acute event:
Stable plaque (thick cap + small lipid core): may just narrow slowly over yearsUnstable plaque (thin cap + large lipid core + strong inflammation): prone to ruptureRupture → platelet aggregation → thrombus → acute occlusion → heart attack / strokeMany heart attacks occur on plaques that only narrow the vessel 30-50% — danger comes not from how narrow it is but from how unstable it is
Why this mechanism dictates the treatment philosophy:
Lowering LDL / ApoB = less raw material burrowing into the wall → plaque progression slows or even regressesThe extra value of statins is plaque stabilization (lowering inflammation), not just lowering a numberControlling blood pressure + quitting smoking + controlling glucose = protecting the endothelium, fewer particles enteringThis is why a single low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls. number is not enough — what matters is the overall 'will plaque grow, and is it stable'
Chapter 4
Diet + lifestyle · realistic effects
Diet + lifestyle · realistic effects
Realistic low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls. reduction from diet is 10-15%, not 'reverse everything'.
Effective dietary interventions (by effect size):
Replace saturated with unsaturated fat (primary lever — substitution beats simple fat reduction):Butter / beef tallow / coconut oil (high saturated) → olive / canola / avocado oilEach 5% energy from saturated → polyunsaturated: LDL-C ↓ ~ 10%Soluble fiber (β-glucan, oats / barley): 5-10 g/day → LDL-C ↓ 5%Plant sterols (sterol-fortified spreads): 2 g/day → LDL-C ↓ 8-10%Soy protein substitution: 25 g/day → LDL-C ↓ 3-5%Nuts 30 g/day: LDL-C ↓ 5%, high-density lipoprotein cholesterol: The so-called 'good cholesterol' — it helps ferry excess cholesterol back to the liver. unchangedDASH / Mediterranean pattern: LDL-C ↓ 8-12%, BP + TG improvedEliminate trans fats (hydrogenated oils): strong evidence — lowers LDL + raises HDL
For high TG / metabolic syndrome:
Limit sugar + fructose + alcohol: TG drops fastestWeight loss 5-10%: TG ↓ 20-30%Exercise (aerobic + RT): TG ↓ 15-25%, HDL-C ↑ 5-10%Fish oil (high-dose EPA 2-4 g/day): TG ↓ 25-40% (atlas supplements/fish-oil)
Lifestyle (benefits independent of diet):
Quit smoking: alone cuts atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease. risk 30-50%, more impactful than LDL-C lowering (yet often ignored)Exercise: 150 min moderate aerobic + 2×/wk RT → broad metabolic improvementWeight loss 5-10%: improves insulin + TG + HDLLimit alcohol: 'moderate ≠ heart-healthy' — the J-curve has been falsified by Mendelian randomizationSleep 7-9 h: deprivation → insulin resistance → worse lipids
Diet vs drugs — when to start medication:
Low risk + borderline LDL-C: lifestyle first, reassess in 3-6 monthsModerate risk + off-target LDL-C: lifestyle + shared decision-making on statinHigh risk / established ASCVD: don't wait for diet to 'fix itself' — start statin + lifestyle in parallelExtremely high LDL-C (≥ 4.9): direct statin, suspect familial hypercholesterolemia (FH)
About 'eating eggs':
Dietary cholesterol from eggs has far less impact than saturated fatMost people can safely eat 1-2 eggs/day (Hu 2019 synthesis)Diabetics / established ASCVD: be slightly conservative (≤ 5/week) — some are 'cholesterol hyper-responders'Look at the overall dietary pattern, not a single food
Atlas connections:
fats-omega-3 (saturated vs unsaturated)nafld (metabolic syndrome co-origin)type-2-diabetes (DM + lipids)hypertension (cardiovascular whole)supplements/red-yeast-rice + supplements/fish-oil (alternative/adjunct discussions)supplements/coq10 (statin-myalgia adjunct)
Effective dietary interventions (by effect size):
Replace saturated with unsaturated fat (primary lever — substitution beats simple fat reduction):Butter / beef tallow / coconut oil (high saturated) → olive / canola / avocado oilEach 5% energy from saturated → polyunsaturated: LDL-C ↓ ~ 10%Soluble fiber (β-glucan, oats / barley): 5-10 g/day → LDL-C ↓ 5%Plant sterols (sterol-fortified spreads): 2 g/day → LDL-C ↓ 8-10%Soy protein substitution: 25 g/day → LDL-C ↓ 3-5%Nuts 30 g/day: LDL-C ↓ 5%, high-density lipoprotein cholesterol: The so-called 'good cholesterol' — it helps ferry excess cholesterol back to the liver. unchangedDASH / Mediterranean pattern: LDL-C ↓ 8-12%, BP + TG improvedEliminate trans fats (hydrogenated oils): strong evidence — lowers LDL + raises HDL
For high TG / metabolic syndrome:
Limit sugar + fructose + alcohol: TG drops fastestWeight loss 5-10%: TG ↓ 20-30%Exercise (aerobic + RT): TG ↓ 15-25%, HDL-C ↑ 5-10%Fish oil (high-dose EPA 2-4 g/day): TG ↓ 25-40% (atlas supplements/fish-oil)
Lifestyle (benefits independent of diet):
Quit smoking: alone cuts atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease. risk 30-50%, more impactful than LDL-C lowering (yet often ignored)Exercise: 150 min moderate aerobic + 2×/wk RT → broad metabolic improvementWeight loss 5-10%: improves insulin + TG + HDLLimit alcohol: 'moderate ≠ heart-healthy' — the J-curve has been falsified by Mendelian randomizationSleep 7-9 h: deprivation → insulin resistance → worse lipids
Diet vs drugs — when to start medication:
Low risk + borderline LDL-C: lifestyle first, reassess in 3-6 monthsModerate risk + off-target LDL-C: lifestyle + shared decision-making on statinHigh risk / established ASCVD: don't wait for diet to 'fix itself' — start statin + lifestyle in parallelExtremely high LDL-C (≥ 4.9): direct statin, suspect familial hypercholesterolemia (FH)
About 'eating eggs':
Dietary cholesterol from eggs has far less impact than saturated fatMost people can safely eat 1-2 eggs/day (Hu 2019 synthesis)Diabetics / established ASCVD: be slightly conservative (≤ 5/week) — some are 'cholesterol hyper-responders'Look at the overall dietary pattern, not a single food
Atlas connections:
fats-omega-3 (saturated vs unsaturated)nafld (metabolic syndrome co-origin)type-2-diabetes (DM + lipids)hypertension (cardiovascular whole)supplements/red-yeast-rice + supplements/fish-oil (alternative/adjunct discussions)supplements/coq10 (statin-myalgia adjunct)
Chapter 5
My lipid panel is off — what now?
My lipid panel is off — what now?
'My lipid panel has arrows — should I worry, should I take a drug?' This is best decided by risk, not by a single number. Work through it step by step.
Q1 · How high is my overall risk (not just low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls.)?
Put age, blood pressure, smoking, diabetes, and cardiovascular history together into a risk calculator (China-PAR recommended for Chinese populations)Established atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease. (heart attack / stroke / prior stent): very high risk — no calculation needed, treat as secondary preventionNo ASCVD: compute 10-year risk to decide how aggressive to beThe same LDL-C number means completely different things in low-risk vs very-high-risk people
Q2 · What is my LDL-C target?
Very high < 1.4 / high < 1.8 / moderate < 2.6 / low < 3.0 mmol/LThe stricter the target, the more one leans toward medication + parallel lifestyle
Q3 · Lifestyle first or straight to a drug?
Low risk + borderline LDL-C: lifestyle first, recheck in 3-6 monthsModerate risk + off-target: lifestyle + shared decision-making with a doctor on a statinHigh risk / established ASCVD / LDL-C ≥ 4.9: don't wait for diet to 'fix itself' — start a statin with parallel lifestyle; LDL-C ≥ 4.9 also warrants screening for familial hypercholesterolemia (FH)
Q4 · Should I measure apolipoprotein B: One sits on every artery-clogging particle, so counting it counts the harmful particles directly. / lipoprotein(a): A largely gene-set lipoprotein particle that independently raises cardiovascular risk.?
LDL-C is enough for most peopleHigh triglycerides / diabetes / obesity / LDL-C at goal but still high-risk: adding ApoB is more accurateMeasure Lp(a) at least once in a lifetime: know whether you carry an inborn genetic high risk
Q5 · On a statin but off-target / intolerant?
Off-target: raise the dose, or add ezetimibe; if still short, add a PCSK9 inhibitorTrue intolerance (< 5%): switch / reduce / alternate-day, or use bempedoic acid which doesn't enter muscleMost 'statin myalgia' is nocebo or comorbid (check vitamin D / thyroid) — don't abandon lipid-lowering at the first ache
The two most overlooked yet highest-ROI moves:
Quit smoking: alone cuts ASCVD risk 30-50%, more impactful than lowering LDL-CDon't expect diet alone to solve it: realistic LDL-C change from diet is ~ 10-15% — it is the foundation, not the whole answer
This island's core stance: lipid management is not about perfecting a number — it is about lowering the probability, over the coming decades, of growing an unstable plaque and having a heart attack or stroke. What matters is the causal chain of overall risk + particle number + plaque stability, not one isolated arrow on a lab report.
Atlas connections: nafld + type-2-diabetes + hypertension + chronic-inflammation (cardiometabolic co-origin) · fats-omega-3 (saturated vs unsaturated) · supplements/fish-oil + red-yeast-rice + coq10 (adjunct / alternative discussions).
Q1 · How high is my overall risk (not just low-density lipoprotein cholesterol: The so-called 'bad cholesterol' — the higher it is, the more plaque tends to build in artery walls.)?
Put age, blood pressure, smoking, diabetes, and cardiovascular history together into a risk calculator (China-PAR recommended for Chinese populations)Established atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease. (heart attack / stroke / prior stent): very high risk — no calculation needed, treat as secondary preventionNo ASCVD: compute 10-year risk to decide how aggressive to beThe same LDL-C number means completely different things in low-risk vs very-high-risk people
Q2 · What is my LDL-C target?
Very high < 1.4 / high < 1.8 / moderate < 2.6 / low < 3.0 mmol/LThe stricter the target, the more one leans toward medication + parallel lifestyle
Q3 · Lifestyle first or straight to a drug?
Low risk + borderline LDL-C: lifestyle first, recheck in 3-6 monthsModerate risk + off-target: lifestyle + shared decision-making with a doctor on a statinHigh risk / established ASCVD / LDL-C ≥ 4.9: don't wait for diet to 'fix itself' — start a statin with parallel lifestyle; LDL-C ≥ 4.9 also warrants screening for familial hypercholesterolemia (FH)
Q4 · Should I measure apolipoprotein B: One sits on every artery-clogging particle, so counting it counts the harmful particles directly. / lipoprotein(a): A largely gene-set lipoprotein particle that independently raises cardiovascular risk.?
LDL-C is enough for most peopleHigh triglycerides / diabetes / obesity / LDL-C at goal but still high-risk: adding ApoB is more accurateMeasure Lp(a) at least once in a lifetime: know whether you carry an inborn genetic high risk
Q5 · On a statin but off-target / intolerant?
Off-target: raise the dose, or add ezetimibe; if still short, add a PCSK9 inhibitorTrue intolerance (< 5%): switch / reduce / alternate-day, or use bempedoic acid which doesn't enter muscleMost 'statin myalgia' is nocebo or comorbid (check vitamin D / thyroid) — don't abandon lipid-lowering at the first ache
The two most overlooked yet highest-ROI moves:
Quit smoking: alone cuts ASCVD risk 30-50%, more impactful than lowering LDL-CDon't expect diet alone to solve it: realistic LDL-C change from diet is ~ 10-15% — it is the foundation, not the whole answer
This island's core stance: lipid management is not about perfecting a number — it is about lowering the probability, over the coming decades, of growing an unstable plaque and having a heart attack or stroke. What matters is the causal chain of overall risk + particle number + plaque stability, not one isolated arrow on a lab report.
Atlas connections: nafld + type-2-diabetes + hypertension + chronic-inflammation (cardiometabolic co-origin) · fats-omega-3 (saturated vs unsaturated) · supplements/fish-oil + red-yeast-rice + coq10 (adjunct / alternative discussions).
References · 7
- Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143. 10.1161/CIR.0000000000000625
- Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., et al. (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias. European Heart Journal, 41(1), 111-188. 10.1093/eurheartj/ehz455
- Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013). Remnant cholesterol as a causal risk factor for ischemic heart disease. Journal of the American College of Cardiology, 61(4), 427-436. 10.1016/j.jacc.2012.08.1026
- Cholesterol Treatment Trialists' (CTT) Collaboration. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376(9753), 1670-1681. 10.1016/S0140-6736(10)61350-5
- Becker, D. J., Gordon, R. Y., Halbert, S. C., French, B., Morris, P. B., & Rader, D. J. (2009). Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Annals of Internal Medicine, 150(12), 830-839. 10.7326/0003-4819-150-12-200906160-00006
- Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., … Nicholls, S. J. (2023). Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine, 388(15), 1353-1364. 10.1056/NEJMoa2215024
- Libby, P., Ridker, P. M., & Hansson, G. K. (2011). Progress and challenges in translating the biology of atherosclerosis. Nature, 473(7347), 317-325. 10.1038/nature10146